Certainly.
With respect to the PMPRB regulations for the type of work we're currently carrying out, they are very much dedicated to early-stage clinical trials—phase one or phase one/two—at which point we wouldn't be approaching that territory of the PMPRB regulations. It's a long answer to say, in short, that it would not impact the clinical trials that we are bringing forward through the research.